Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/23895
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yasara, N. | |
dc.contributor.author | Wickramarathne, N. | |
dc.contributor.author | Silva, I. | |
dc.contributor.author | Hameed, N. | |
dc.contributor.author | Attanayaka, A.M.K.R. | |
dc.contributor.author | Jayasinghe, V.L. | |
dc.contributor.author | Gunathilaka, P.A.C.K. | |
dc.contributor.author | Wickramasinghe, N. | |
dc.contributor.author | Rodrigo, R. | |
dc.contributor.author | Perera, L | |
dc.contributor.author | Perera, P.S. | |
dc.contributor.author | Mettananda, K.C.D. | |
dc.contributor.author | Manamperi, A. | |
dc.contributor.author | Premawardhena, A. | |
dc.contributor.author | Mettananda, S. | |
dc.date.accessioned | 2021-11-16T05:50:31Z | |
dc.date.available | 2021-11-16T05:50:31Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Sri Lanka Medical Association, 134th Anniversary International Medical Congress. 2021; 162 | en_US |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/23895 | |
dc.description | Poster Presentation Abstract, “Professional Excellence Towards Holistic Healthcare”, 134th Anniversary International Medical Congress, Sri Lanka Medical Association, 21st – 24th September 2021, Colombo, Sri Lanka | en_US |
dc.description.abstract | Introduction and objectives Hydroxyurea induces fetal haemoglobin in vitro however, its clinical usefulness in β-thalassaemia is unclear. Here, we aim to assess the efficacy and safety of oral hydroxyurea in patients with transfusion dependent β-thalassaemia. Methods A phase 3 randomized double-blind placebo-controlled clinical trial was conducted at Colombo North Teaching Hospital in 2019/20. Sixty patients with transfusion dependent β-thalassaemia were randomized into hydroxyurea (10-20mg/kg/day) or placebo groups. Transfused blood volume, pre-transfusion haemoglobin, fetal haemoglobin and adverse effects were monitored during 6-month treatment and post-treatment periods. The study was approved by the ethics committee of University of Kelaniya and registered in Sri Lanka Clinical Trials Registry (SLCTR/2018/024). Results Fifty-four (hydroxyurea-27; placebo-27) patients completed the trial. Mean pre-transfusion haemoglobin (8.2±0.8g/ dLvs8.0±0.88g/dL, p=0.43) and fetal haemoglobin levels (7.9±11.2%vs4.6±4.3%, p=0.17) were higher in hydroxyurea group compared to placebo. Also, transfused blood volume was lower in the hydroxyurea group (94±29ml/kgvs102±28ml/kg, p=0.34). However, none were statistically significant. Based on elevation of fetal haemoglobin (>1.5% from baseline), we identified 12/27 patients who respond well to hydroxyurea (hydroxyurea-responders). Hydroxyurea-responders required significantly lower blood volume (77±27ml/kg) compared to non-responders (108±24ml/kg, p<0.01) and placebo group (102±28ml/kg, p<0.05). HbE β-thalassaemia sub-type (p<0.01) and Xmn1 polymorphism of γ-globin gene (p<0.05) were significant predictors of response to hydroxyurea. No serious side effects due to hydroxyurea were reported. Conclusion Over 40% of patients with transfusion dependent β-thalassaemia- specifically those with HbE β-thalassaemia and Xmn1 polymorphism of γ-globin gene- responded to hydroxyurea and required 25% less blood compared to controls. No serious adverse effects were reported following hydroxyurea treatment. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sri Lanka Medical Association | en_US |
dc.subject | β-thalassaemia | en_US |
dc.title | Hydroxyurea for transfusion dependent β-thalassaemia: A randomized double-blind placebo-controlled clinical trial | en_US |
dc.type | Conference Abstract | en |
Appears in Collections: | Conference Papers |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.